We could not find any results for:
Make sure your spelling is correct or try broadening your search.
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 09/30/10 -- www.stockcall.com/ offers investors comprehensive research on the drug delivery industry and has completed analytical research on Biovail...
Valeant Pharmaceuticals International (NYSE: VRX) and Biovail Corporation (NYSE/TSX: BVF) announced that at today’s Special Meetings, each of which had a quorum of shareholders...
("Bioval Founder Opposes Merger With Valeant," at 8:38 p.m. EDT, misspelled the company name in the headline. The correct version follows:) By Andy Georgiades Of DOW JONES NEWSWIRES Biovail...
By Andy Georgiades Of DOW JONES NEWSWIRES Biovail Corp.'s (BVF) founder is joining some California government officials in opposing the company's merger with Valeant Pharmaceuticals International...
By Andy Georgiades Of DOW JONES NEWSWIRES Two top California government officials are adding their dissenting voices to the proposed merger of Canada's Biovail Corp. (BVF) and California-based...
Andy Georgiades Of Dow Jones Newswires Days before shareholders of Canada's Biovail Corp. (BVF) and Valeant Pharmaceuticals International (VRX) are scheduled to vote on their merger agreement, two...
Standard & Poor's Announces Changes to U.S. Indices PR Newswire NEW YORK, Sept. 22 NEW YORK, Sept. 22 /PRNewswire/ -- S&P SmallCap 600 constituent Baldor Electric Co. (NYSE: BEZ) will replace...
Valeant and Biovail Announce Valeant's Intention to Declare a Special Dividend to Valeant Stockholders Upon Obtaining Shareholder Approval, Financing and Satisfaction of Other Closing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions